Multicenter Evaluation of Bactec MGIT 960 System for Second-Line Drug Susceptibility Testing of Mycobacterium tuberculosis Complex

ABSTRACT The Bactec MGIT 960 system for testing susceptibility to second-line drugs was evaluated with 117 clinical strains in a multicenter study. The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide. The critical concentration established for levofloxacin and amikacin was 1.5 μg/ml, that established for capreomycin was 3.0 μg/ml, and that established for ethionamide was 5.0 μg/ml. The overall level of agreement between the agar proportion method and the MGIT 960 system was 96.4%, and the levels of agreement for the individuals drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionamide. The rate of reproducibility of the drug susceptibility testing results between the participating laboratories was 99.5%.

[1]  S. Shenai,et al.  Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  F. Portaels,et al.  Rapid Detection of Mycobacterium tuberculosis Resistance to Second-Line Drugs by Use of the Manual Mycobacterium Growth Indicator Tube System , 2008, Journal of Clinical Microbiology.

[3]  T. Porco,et al.  Extensively drug-resistant tuberculosis: new strains, new challenges , 2008, Expert review of anti-infective therapy.

[4]  R. O'brien,et al.  Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. , 2008, American journal of respiratory and critical care medicine.

[5]  K. Kam,et al.  Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs , 2008 .

[6]  S. Rüsch-Gerdes,et al.  Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens , 2007, Journal of Clinical Microbiology.

[7]  G. Bai,et al.  Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.

[8]  I. Smith,et al.  XDR tuberculosis--implications for global public health. , 2007, The New England journal of medicine.

[9]  V. Thomsen,et al.  Rapid Genotypic Detection of Rifampin- and Isoniazid-Resistant Mycobacterium tuberculosis Directly in Clinical Specimens , 2006, Journal of Clinical Microbiology.

[10]  F. Drobniewski,et al.  Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosis , 2006, Journal of Clinical Microbiology.

[11]  S. Rüsch-Gerdes,et al.  Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials , 2006, Journal of Clinical Microbiology.

[12]  J. Gerberding,et al.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. , 2006, MMWR. Morbidity and mortality weekly report.

[13]  S. Kim.  Drug-susceptibility testing in tuberculosis: methods and reliability of results , 2005, European Respiratory Journal.

[14]  E. Desmond,et al.  Validation of the Use of Middlebrook 7H10 Agar, BACTEC MGIT 960, and BACTEC 460 12B Media for Testing the Susceptibility of Mycobacterium tuberculosis to Levofloxacin , 2004, Journal of Clinical Microbiology.

[15]  E. Desmond,et al.  Rapid Detection of Isoniazid and Rifampin Resistance Mutations in Mycobacterium tuberculosis Complex from Cultures or Smear-Positive Sputa by Use of Molecular Beacons , 2004, Journal of Clinical Microbiology.

[16]  C. Scarparo,et al.  Evaluation of the Fully Automated BACTEC MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide, Streptomycin, Isoniazid, Rifampin, and Ethambutol and Comparison with the Radiometric BACTEC 460TB Method , 2004, Journal of Clinical Microbiology.

[17]  V. Thomsen,et al.  Direct Detection of Multidrug-Resistant Mycobacterium tuberculosis in Clinical Specimens in Low- and High-Incidence Countries by Line Probe Assay , 2003, Journal of Clinical Microbiology.

[18]  E. Tortoli,et al.  Evaluation of Automated BACTEC MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Four Major Antituberculous Drugs: Comparison with the Radiometric BACTEC 460TB Method and the Agar Plate Method of Proportion , 2002, Journal of Clinical Microbiology.

[19]  S. Rüsch-Gerdes,et al.  Multicenter Evaluation of Fully Automated BACTEC Mycobacteria Growth Indicator Tube 960 System for Susceptibility Testing of Mycobacterium tuberculosis , 2002, Journal of Clinical Microbiology.

[20]  A. Mirzabekov,et al.  Identification of Rifampin-Resistant Mycobacterium tuberculosis Strains by Hybridization, PCR, and Ligase Detection Reaction on Oligonucleotide Microchips , 2001, Journal of Clinical Microbiology.

[21]  J. Kornblum,et al.  Multicenter Laboratory Validation of Susceptibility Testing of Mycobacterium tuberculosis against Classical Second-Line and Newer Antimicrobial Drugs by Using the Radiometric BACTEC 460 Technique and the Proportion Method with Solid Media , 1999, Journal of Clinical Microbiology.

[22]  J. T. Crawford,et al.  The resurgence of tuberculosis: is your laboratory ready? , 1993, Journal of clinical microbiology.

[23]  D. Mitchison,et al.  Comparison of methods for testing the sensitivity of Mycobacterium tuberculosis to ethionamide. , 1966, Tubercle.